Five V Capital has led a $12 million Series A investment in Lyrebird Health, an Australian healthtech company transforming clinical documentation through its innovative AI medical scribe solution.
Target Information
Lyrebird Health is an innovative healthtech company based in Australia, focused on revolutionizing clinical documentation processes. The company has developed an AI-driven medical scribe that securely listens to doctor-patient consultations and generates customized clinical notes. These notes seamlessly integrate into electronic medical record (EMR) systems like Best Practice Software and Magentus, ensuring that sensitive data remains within Australia.
Currently, Lyrebird Health manages over 30,000 consultations daily across Australia, significantly reducing the administrative workload for healthcare providers. Prestigious hospitals, including the Gold Coast Hospital and Health Service and Alder Hey Children's NHS Foundation Trust, have reported notable enhancements in operational efficiency, the quality of documentation, and clinician satisfaction as a result of adopting Lyrebird’s solutions.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The Australian healthtech sector is rapidly evolving, driven by advancements in technology and a growing demand for innovative solutions to improve patient care. The increasing adoption of AI and digital health tools is reshap
Similar Deals
Five V Capital
invested in
Lyrebird Health
in
in a Series A deal
Disclosed details
Transaction Size: $12M